病例报告

以肌阵挛起病的ATP13A2基因突变相关神经变性病一例并文献复习

  • 张炜炜 ,
  • 何晓勤 ,
  • 吴瑜 ,
  • 肖勤 ,
  • 谭玉燕
展开
  • 1.上海交通大学医学院附属瑞金医院无锡分院神经内科,江苏 无锡 214000
    2.上海交通大学医学院附属瑞金医院神经内科,上海 200025
    3.海南省人民医院/海南医科大学附属海南医院,海南 海口 570311
谭玉燕 E-mail:yuyantan00@126.com

收稿日期: 2024-10-09

  修回日期: 2025-04-11

  录用日期: 2025-05-21

  网络出版日期: 2026-02-25

基金资助

无锡市太湖人才计划

ATP13A2 gene mutation-related neurodegenerative diseases with myoclonus onset:a case report and literature review

  • ZHANG Weiwei ,
  • HE Xiaoqin ,
  • WU Yu ,
  • XIAO Qin ,
  • TAN Yuyan
Expand
  • 1. Department of Neurology, Wuxi branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Jiangsu Wuxi 214000, China
    2. Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    3. Hainan Provincial People's Hospital/Hainan Hospital affiliated to Hainan Medical University, Hainan Haikou 570311, China

Received date: 2024-10-09

  Revised date: 2025-04-11

  Accepted date: 2025-05-21

  Online published: 2026-02-25

摘要

ATP13A2基因突变与Kufor-Rakeb综合征(Kufor-Rakeb syndrome,KRS)、遗传性痉挛性截瘫78型(spastic paraplegia, SPG78)、神经元脑苷脂沉积症12型、肌萎缩侧索硬化等多种神经变性疾病相关。本文报道1例罕见的ATP13A2基因纯合突变患者(Exon12 c.1062G>T:p.Lys354Asn)。该患者为35岁女性,以双上肢不自主抖动起病,这种抖动考虑为姿势及动作诱发肌阵挛,逐渐累及双下肢,伴有运动迟缓、下肢痉挛步态、认知功能障碍及精神行为异常。肌电分析示,患者站立位和半卧位可见双下肢阵发性肌电发放,发放频率不规则;体感诱发电位检查显示,P25波幅明显增高,提示皮层来源肌阵挛。予患者左乙拉西坦联合氯硝西泮改善肌阵挛,左旋多巴/苄丝肼联合普拉克索抗帕金森症状,患者的肌阵挛、肌强直、运动迟缓均较前明显改善,可独立行走。该患者突变位点在PubMed数据库、中华医学期刊全文数据库、万方数据库、知网数据库中均未见报道,氨基酸保守性分析显示该位点在人以及大鼠、小鼠、牛、黑猩猩、猪6种脊椎动物中高度保守,根据美国医学遗传学与基因组学学会遗传变异分类标准及指南,该变异为可能致病性变异,具有KRS、SPG78表型叠加特征。皮层来源的四肢粗大肌阵挛为该基因首次报道的表型,本次报道扩大了其临床表型谱。

本文引用格式

张炜炜 , 何晓勤 , 吴瑜 , 肖勤 , 谭玉燕 . 以肌阵挛起病的ATP13A2基因突变相关神经变性病一例并文献复习[J]. 诊断学理论与实践, 2026 , 25(01) : 90 -95 . DOI: 10.16150/j.1671-2870.2026.01.013

Abstract

Mutations in the ATP13A2 gene are associated with various neurodegenerative diseases, including Kufor-Rakeb syndrome (KRS), hereditary spastic paraplegia type 78 (SPG78), neuronal ceroid lipofuscinosis type 12 (CLN12), and amyotrophic lateral sclerosis (ALS). This study reports a case of a rare homozygous mutation in the ATP13A2 gene (Exon12 c.1062G>T: p.Lys354Asn). The patient, a 35-year-old female, initially presented with involuntary tremors in both upper limbs, which were considered posture- and action-induced myoclonus. The symptoms progressively involved both lower limbs, accompanied by bradykinesia, spastic gait in the lower limbs, cognitive impairment, and psychiatric behavioral abnormalities. Electromyography (EMG) revealed paroxysmal EMG discharges in both lower limbs when the patient was in the standing and semi-recumbent positions, with irregular discharge frequencies. Somatosensory evoked potential testing indicated a significant increase in P25 amplitude, suggesting a cortical origin of the myoclonus. The patient was treated with levetiracetam combined with clonazepam to alleviate the myoclonus and levodopa/benserazide combined with pramipexole for parkinsonian symptoms. Significant improvements were observed in myoclonus, muscle rigidity, and bradykinesia, and the patient regained independent ambulation. This mutation site in this patient has not been previously reported in the PubMed database, the Chinese Medical Journal (CMJ) Full-Text Database, Wanfang Database, or the China National Knowledge Infrastructure (CNKI). Amino acid conservation analysis indicated that this site was highly conserved among six vertebrate species, including humans, rats, mice, cattle, chimpanzees, and pigs. According to the genetic mutation classification standards and guidelines of the American College of Medical Genetics and Genomics (ACMGG), this mutation is considered likely pathogenic, exhibiting overlapping phenotypic features of KRS and SPG78. The phenotype of coarse limb myoclonus of cortical origin represents the first reported case associated with this gene, thereby expanding its clinical phenotypic spectrum.

参考文献

[1] FUJII T, NAGAMORI S, WIRIYASERMKUL P, et al. Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H+,K+-ATPase[J]. Nat Commun, 2023, 14(1):2174.
[2] CROUCHER K M, FLEMING S M. ATP13A2 (PARK9) and basal ganglia function[J]. Front Neurol, 2024,14:1252400.
[3] RICHARDS S, AZIZ N, BALE S, et al. Standardsand guidelines for theInterpretation of sequence variants:ajoint consensus recommendation of the American College of Medical Geneticsand Genomics and the Association for Molecular Pathology[J]. GenetMed, 2015, 17(5):405-424.
[4] GOWDA V K, SRINIVASAN V M, SHIVAPPA S K. Kufor-Rakeb syndrome/parkinson disease type 9[J]. Indian J Pediatr, 2020, 87(3):231-232.
[5] MARTINO D, MELZI V, FRANCO G, et al. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation[J]. Parkinso-nism Relat Disord, 2015, 21(11):1378-1380.
[6] WALLER S E, WILLIAMS L, MORALES-BRICE?O H, et al. Teaching video neuroimage: Facial-Faucial-Finger Myoclonus in Kufor-Rakeb syndrome[J]. Neurology, 2022, 99(4):172-173.
[7] ROHANI M, LANG A E, SINA F, et al. Action myoclonus and seizure in Kufor‐Rakeb syndrome[J]. Mov Disord Clin Pract, 2017, 5(2):195-199.
[8] ODAKE Y, KOH K, TAKIYAMA Y, et al. Identification of a novel mutation in ATP13A2 associated with a complicated form of hereditary spastic paraplegia[J]. Neurology Genetics, 2020, 6(5):e514.
[9] ALEJANDRO E C, SHAUN M, TEODORA C, et al. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78)[J]. Brain, 2017(2):287-305.
[10] 周继秀, 杨艺, 刘娟, 等. ATP13A2基因28和21号外显子的c.3367C>G和c.2278G>A突变所致Kufor-Rakeb综合征一例[J]. 中华医学杂志, 2020, 100(31):2473-2474.
  ZHOU J X, YANG Y, LIU J, et al. A case of Kufor-Rakeb syndrome caused by c.3367C>G and c.2278G>A mutations in exons 28 and 21 of the ATP13A2 gene[J]. Chin Med J, 2020, 100(31):2473-2474.
[11] 魏小金, 钱方媛, 吴雨晨, 等. ATP13A2基因突变致Kufor-Rakeb综合征1例报道并文献复习[J]. 中华神经科杂志, 2024, 57(5):467-472.
  WEI X J, QIAN F Y, WU Y C, et al. A case report of Kufor-Rakeb syndrome due to ATP13A2 gene mutation and a literature review[J]. Chin J Neurol, 2024, 57(5):467-472.
[12] WILLIAMS D R, HADEED A, AL-DIN A S, et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia[J]. Mov Disord, 2005, 20(10):1264-1271.
[13] BALINT B, DAMASIO J, MAGRINELLI F, et al. Psychia-tric manifestations of ATP13A2 mutations[J]. Mov Disord Clin Pract, 2020, 7(7):838-841.
[14] SATOLLI S, DI FONZO A, ZANOBIO M, et al. Kufor Rakeb syndrome and pyramidal signs due to novel ATP13A2 mutations[J]. Neurol Sci, 2023, 44(10):3723-3725.
[15] PIETRZAK A, BADURA-STRONKA M, KANGAS-KONTIO T, et al. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome[J]. Folia Neuropathol, 2019, 57(3):285-294.
[16] COVY J P, WAXMAN E A, GIASSON B I. Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants[J]. J Neurosci Res, 2012, 90(12):2306-2316.
[17] NITA D A, MOLE S E, MINASSIAN B A. Neuronal ceroid lipofuscinoses[J]. Epileptic Disord, 2016, 18(S2):73-88.
[18] 王刚, 徐刚, 谢心怡, 等. 中国帕金森病报告2025[J]. 神经病学与神经康复学杂志, 2025, 21(2):63-98.
  WAGN G, XU G, XIE X Y, et al. China Parkinson's disease report, 2025[J]. J Neurol Neurorehabil, 2025, 21(2):63-98.
[19] SU L J, WANG Y L, HAN T, et al. Antimyoclonic effect of levetiracetam and clonazepam combined treatment on myoclonic epilepsy with Ragged-Red fiber syndrome with m.8344A>G mutation[J]. Chin Med J (Engl), 2018, 131(20):2433-2438.
[20] PENA A B, CAVINESS J N. Physiology-based treatment of Myoclonus[J]. Neurotherapeutics, 2020, 17(4):1665-1680.
[21] KOLA S, MEKA S S L, SYED T F, et al. Kufor Rakeb syndrome with novel mutation and the role of deep brain stimulation[J]. Mov Disord Clin Pract, 2022, 9(7):1003-1007.
文章导航

/